Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform...

Full description

Bibliographic Details
Main Authors: Satoshi Inoue, Rameshwar Patil, Jose Portilla-Arias, Hui Ding, Bindu Konda, Andres Espinoza, Dmitriy Mongayt, Janet L Markman, Adam Elramsisy, H Westley Phillips, Keith L Black, Eggehard Holler, Julia Y Ljubimova
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3280290?pdf=render